Literature DB >> 7958478

Recombinant Salmonella vectors in vaccine development.

R Curtiss1, S M Kelly, S A Tinge, C O Tacket, M M Levine, J Srinivasan, M Koopman.   

Abstract

A diversity of means are available for the attenuation of Salmonella which can be used to immunize animals and humans orally to elicit mucosal, humoral and cellular immune responses. Avirulent Salmonellae can be genetically engineered to express foreign antigens and the recombinant avirulent Salmonellae are capable of stable, high-level expression of the foreign antigen in the orally immunized animal or human host. The resulting vaccines are safe, efficacious, and are easy and economical to use.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7958478

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN： 0301-5149


  12 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  A biologically conjugated polysaccharide vaccine delivered by attenuated Salmonella Typhimurium provides protection against challenge of avian pathogenic Escherichia coli O1 infection.

Authors:  Yue Han; Qing Liu; Jie Yi; Kang Liang; Yunan Wei; Qingke Kong
Journal:  Pathog Dis       Date:  2017-11-30       Impact factor: 3.166

Review 4.  Overview of vaccines.

Authors:  G Ada
Journal:  Mol Biotechnol       Date:  1997-10       Impact factor: 2.695

5.  The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.

Authors:  J Benyacoub; S Hopkins; A Potts; S Kelly; J P Kraehenbuhl; R Curtiss; P De Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

6.  Characterization and immunogenicity of Salmonella typhimurium SL1344 and UK-1 delta crp and delta cdt deletion mutants.

Authors:  X Zhang; S M Kelly; W S Bollen; R Curtiss
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

7.  Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis.

Authors:  Wei Xin; Soo-Young Wanda; Yuhua Li; Shifeng Wang; Hua Mo; Roy Curtiss
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

8.  Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment.

Authors:  Wei Kong; Soo-Young Wanda; Xin Zhang; Wendy Bollen; Steven A Tinge; Kenneth L Roland; Roy Curtiss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

9.  The Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine.

Authors:  Wei Xin; Soo-Young Wanda; Xiangmin Zhang; Javier Santander; Giorgio Scarpellini; Karen Ellis; Praveen Alamuri; Roy Curtiss
Journal:  Infect Immun       Date:  2012-08-06       Impact factor: 3.441

10.  Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant.

Authors:  P J Valentine; B P Devore; F Heffron
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.